The other scale uses different information about the rash to track changes in its size and severity over time. Dupixent was compared with placebo in every study. The people in the studies did ...

Dupixent is the first new targeted therapy for ... general ill feeling, itching, skin rash, swollen lymph nodes, nausea or vomiting, or cramps in your stomach-area. Eye problems.

The U.S. Food and Drug Administration approved the use of Sanofi and Regeneron's blockbuster drug Dupixent for patients with a type of skin condition, the two companies said on Friday.

The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adults and adolescents with chronic spontaneous urticaria. The approval is for patients 12 years and ...

Sanofi and Regeneron’s Dupixent (dupilumab) has been approved by the US Food and Drug Administration (FDA) for chronic spontaneous urticaria (CSU). The drug has been authorised to treat the ...

Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in disease severity and itch Dupixent also ...

In two clinical studies, Dupixent showed reductions in itch severity and urticaria activity at 24 weeks, as well as an increased likelihood of well-controlled disease or complete response at 24 ...

From breaking news to special features, we're on it! Join the NonStop Local Chord group and always be in the know. WEDNESDAY, April 23, 2025 (HealthDay News) -- The U.S. Food and Drug ...

WEDNESDAY, April 23, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adults and adolescents with chronic spontaneous urticaria.